Home » Stocks » PROF

Profound Medical Corp. (PROF)

Stock Price: $26.37 USD 0.99 (3.90%)
Updated Jan 21, 2021 4:00 PM EST - Market closed
Market Cap 515.50M
Revenue (ttm) 4.22M
Net Income (ttm) -15.41M
Shares Out 11.85M
EPS (ttm) -1.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 21
Last Price $26.37
Previous Close $25.38
Change ($) 0.99
Change (%) 3.90%
Day's Open 25.47
Day's Range 24.91 - 26.80
Day's Volume 118,374
52-Week Range 6.88 - 26.80

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Seeking Alpha - 1 week ago

I have put an emphasis on value in 2021; however, I am not sitting still in my aggressive portfolio. I have added 2 new positions and added to a third. All 3 companies look to benefit from a r...

Other stocks mentioned: KLR, TLS
GlobeNewsWire - 2 weeks ago

TORONTO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound”), a commercial-stage medical device company that develops and markets customizable, incisio...

GlobeNewsWire - 1 month ago

TORONTO, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which ...

GlobeNewsWire - 1 month ago

TORONTO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) announced today that Sonalleve® has received U.S. Food and Drug Administr...

GlobeNewsWire - 1 month ago

TORONTO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which ...

Seeking Alpha - 2 months ago

Profound Medical has unique differentiators via their TULSA-PRO procedure that provide a breakthrough in an otherwise complex treatment domain. The company has faced headwinds from COVID-19 th...

GlobeNewsWire - 2 months ago

TORONTO, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which ...

Seeking Alpha - 2 months ago

Profound Medical Corp. (PROF) CEO Arun Menawat on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

TORONTO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which ...

GlobeNewsWire - 3 months ago

TORONTO, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which ...

GlobeNewsWire - 4 months ago

TORONTO, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies w...

Seeking Alpha - 5 months ago

Profound Medical: Momentum Continues To Build

GlobeNewsWire - 5 months ago

TORONTO, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies wh...

Seeking Alpha - 5 months ago

Profound Medical Corp. (PROF) CEO Arun Menawat on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

PROFOUND MEDICL (PROF) delivered earnings and revenue surprises of -43.48% and -1.44%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 5 months ago

TORONTO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies wh...

GlobeNewsWire - 5 months ago

TORONTO, July 22, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies wh...

GlobeNewsWire - 6 months ago

TORONTO, July 21, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce that it has closed its previously-announced und...

GlobeNewsWire - 6 months ago

TORONTO, July 15, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the pricing of an underwritten public offering ...

GlobeNewsWire - 6 months ago

TORONTO, July 15, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce that it intends to file a preliminary prospectu...

Zacks Investment Research - 6 months ago

Profound Medical (PROF) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Seeking Alpha - 7 months ago

TULSA-PRO, the most flexible prostate treatment on the market.

GlobeNewsWire - 8 months ago

TORONTO, May 20, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual and Special ...

Seeking Alpha - 8 months ago

Profound Medical Corp. (PROF) CEO Dr.

Zacks Investment Research - 8 months ago

PROFOUND MEDICL (PROF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 8 months ago

Profound Medical: The Prostate Market Disruptor

Seeking Alpha - 9 months ago

Profound Medical, The Apple Of The Prostate Arena

GlobeNewsWire - 11 months ago

TORONTO, Feb. 04, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable, inc...

Seeking Alpha - 11 months ago

Profound Medical: Non-Surgical Prostatectomy Is Profound

GlobeNewsWire - 1 year ago

TORONTO, Jan. 10, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable, inc...

About PROF

Profound Medical operates as a medical technology company develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases, as well as non-invasive treatment of uterine fibroids. Pro... [Read more...]

Industry
Medical Devices
CEO
Dr. Arun Swarup Menawat
Employees
75
Stock Exchange
NASDAQ
Ticker Symbol
PROF
Full Company Profile

Financial Performance

In 2019, PROF's revenue was 5.53 million, an increase of 112.41% compared to the previous year's 2.60 million. Losses were -20.19 million, -2.75% less than in 2018.

Financial numbers in millions CAD.
Financial Statements